Business Wire

Eaton’s Vehicle Group Secures U.S. Department of Energy Grant to Develop Emissions-reducing Technologies for the Agricultural Sector

16.12.2021 21:15:00 EET | Business Wire | Press release

Share

Power management company Eaton today announced its Vehicle Group has secured a $2.4 million grant from the U.S. Department of Energy (DOE) to develop new technologies to reduce emissions from agricultural equipment. This grant will accelerate Eaton’s progress in achieving its 2030 Sustainability Targets. By 2030, the company aims to reduce emissions from its solutions and throughout its value chain by 15%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216005939/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Eaton’s variable valve actuation technologies are an ideal solution for reducing emissions produced by agricultural implements. (Photo: Business Wire)

Under the grant, Eaton plans to develop technologies that simultaneously reduce greenhouse gas (GHG) by 10% and nitrogen oxides (NOx) by 90% for agricultural powertrains designed for multiple-duty cycles. The technologies are required to span application diversity in the segment while being both cost-efficient and robust. Separately, Eaton also received a $4.9 million grant to develop a new compact and modular solid-state transformer to reduce the cost and size of DC fast-charging systems.

“Off-highway sector emissions levels, including in the agricultural segment, significantly lag behind on-road applications due to a lack of technology solutions,” said Dr. Mihai Dorobantu, director, Technology Planning and Government Affairs, Eaton’s Vehicle Group. “This grant could enable significant reductions in both GHG and NOx emissions that would then drive the technology and its benefits nationwide and help us meet our corporate sustainability objectives. The DOE funding supports our ongoing work to develop technologies that reduce emissions in applications that are difficult to decarbonize. The funding also enables research partnerships to optimize architectures and components.”

To achieve the grant’s objective, Eaton’s Vehicle Group will develop new components for agricultural applications and will modify existing technologies developed for commercial vehicles, including engine and aftertreatment systems. Agricultural solutions differ from advanced on-road technologies because they are used in unique and varying operating cycles.

An expansive portfolio of technologies will be leveraged to achieve target goals

By partnering with leading engine manufacturers, Eaton plans to achieve the DOE targets through innovative technologies that provide higher engine compression ratios, reduce friction and increase turbo machinery efficiency while minimizing mechanical losses.

Eaton will adapt its line of variable-valve actuation (VVA) solutions, originally designed for commercial vehicles, for agricultural use. Eaton’s VVA technologies are based on two building blocks — a rocker with a switchable capsule, and a split rocker for full deactivation. By combining these two building blocks, several VVA strategies can be utilized in virtually any engine architecture — from single and dual overhead cam to cam-in-designs, for engine displacements ranging from 2.0 to 15.0 liters.

Cylinder deactivation (CDA) is a VVA technology that consists of deactivating the intake and exhaust valve opening, as well as the fuel injection on some of the cylinders when the engine is running at low load. CDA is an ideal solution for commercial vehicles that make frequent stops, as well as many agricultural implements. CDA can reduce NOx emissions by up to 40% and carbon dioxide (CO2) by 5%-8%.

Eaton will also focus on active catalyst heating technology to assist with exhaust thermal management as part of achieving the DOE’s targets. Active heating solutions provide heat directly to the vehicle’s aftertreatment system, reducing harmful NOx emissions by warming the selective catalytic reduction (SCR) catalyst to approximately 200-250 degrees Celsius as quickly as possible, and maintaining this temperature during periods of low-load operation.

Additionally, Eaton plans to leverage its positive-displacement TVS® exhaust gas recirculation (EGR) pump to meet the program’s objectives. The EGR pump complements a high-efficiency turbocharger to reduce engine pumping losses, thereby increasing fuel economy and lowering emissions. Because the pump is a positive-displacement device, the engine controller uses the pump speed signal, as well as other Controller Area Network (CAN) sensor data, to accurately calculate EGR mass flow rate.

“This program is foundational to creating two market drivers in the off-highway segment —upcoming regulations to lower GHG and NOx emissions across the segment, and a significant economic benefit generated for end users,” Dorobantu said.

The DOE DC fast-charging grant aims to significantly reduce the time it takes to install charging infrastructures at end-user facilities. Eaton’s new technology will feature advanced components and an innovative cooling approach, eliminating the need for multiple power conversion devices. The goal is to reduce charging infrastructure barriers to commercial electric vehicle deployment by minimizing the need for facility modifications and allowing for charging installations in remote areas. The grant aligns with the DOE’s commitment to have zero-emission vehicles make up half of all vehicles sold in America by 2030 and achieve net-zero emissions economywide by 2050.

The grant also supports Eaton’s Vehicle Group and eMobility business's mission to produce sustainable solutions that enhance vehicle efficiency, safety and performance. Our Vehicle products include emission control components, engine valves, valvetrain systems, superchargers, transmissions, clutches and torque management systems. Our eMobility portfolio includes intelligent power electronics, reliable power distribution and protection solutions, and efficient power systems for electrified vehicles.

Learn more about Eaton’s Vehicle Group and eMobility businesses.

Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 85,000 employees. For more information, visit www.eaton.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Thomas Nellenbach
thomasjnellenbach@eaton.com
(216) 333-2876 (cell)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 15:00:00 EEST | Press release

Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar

ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 15:00:00 EEST | Press release

ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful innovation to patients through technologies that advance precision, safety, and the overall treatment experience,” said Sheraz Daya, MD, Medical Director and Founder of Centre for Sight. “We are proud to be the first center globally

BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 15:00:00 EEST | Press release

BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures and HEPATOMUNE® tri-cultures. Additionally, Christian Smith, Scientist I, R&D at BioIVT will present a poster titled "Therapeutic Reversal of Established Steatosis Usin

IHS Towers Publishes 2025 Sustainability Report26.5.2026 13:34:00 EEST | Press release

IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi

Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 13:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye